Now, more than 25 years into her journey with vitiligo, Lisa reflects on the impact of vitiligo and how she’s managed the ...

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...

A new clinical study highlighted the potential of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, as an effective ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...